The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Rs. 40 cr buyback, 200% dividend announced
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The submission is backed by positive results from the Phase 3 AFFIRM study
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
Subscribe To Our Newsletter & Stay Updated
